Despite ambitions to streamline regulatory review, FDA’s Elsa platform has been prone to hallucinations, prompting internal scrutiny and questions about AI reliability and governance.
Chris Mazzolini
Advertisement
Articles by Chris Mazzolini
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: Real-Time Evidence Generation, Protocol Digitization, and Decentralized Trial Flexibility
2
ACT Brief: Mixed FSP Strategy, DIA Meeting Trends, and Patient Voice in Oncology
3
ICON Selects Microsoft as Preferred Technology Partner to Scale Agentic AI Platform Across Clinical Trial Lifecycle
4
2026 DIA Global Annual Meeting: Stacy Hurt of Parexel on Federated AI, the Patient Voice, and Accountability for Patient Needs
5